MedTrace Logo

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-10

No results posted yet for this study

Summary

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

Conditions

  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Transformed Lymphoma
  • Secondary Central Nervous System Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Caspian Oliai, MD · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256641 on ClinicalTrials.gov